DYAI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DYAI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Dyadic International's PE Ratio without NRI is 0.00. Dyadic International's 5-Year EBITDA growth rate is -1.90%. Therefore, Dyadic International's PEG Ratio for today is N/A.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Dyadic International's PEG Ratio or its related term are showing as below:
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
The historical data trend for Dyadic International's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dyadic International Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
PEG Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
Dyadic International Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
PEG Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Dyadic International's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Dyadic International's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Dyadic International's PEG Ratio falls into.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.
Dyadic International's PEG Ratio for today is calculated as
PEG Ratio | = | PE Ratio without NRI | / | 5-Year EBITDA Growth Rate* |
= | / | -1.90 | ||
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Dyadic International (NAS:DYAI) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Thank you for viewing the detailed overview of Dyadic International's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Ronen Tchelet | officer: VP of Research and Bus. Dvlpmt | 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477 |
Mark A Emalfarb | director, 10 percent owner, officer: President, CEO & Chairman | C/O DYADIC INTERNATIONAL, INC., 140 INTRACOASTAL POINT DRIVE, SUITE 404, JUPITER FL 33477-5094 |
Joseph P Hazelton | officer: Chief Business Officer | 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER FL 33477 |
Francisco Trust Under Agreement Dated February 28, 1996 | 10 percent owner | C/O ROBERT S. LEVIN, ESQ., TRUSTEE, 180 NORTH LASALLE STREET, SUITE 3200, CHICAGO IL 60601 |
Patrick K. Lucy | director | C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121 |
Matthew S. Jones | officer: Managing Dir of BD & Licensing | 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477 |
Seth Herbst | director | 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477 |
Barry Buckland | director | C/O DYADIC INTERNATIONAL, INC., 140 INTERCOASTAL POINTE DR SUITE 404, JUPITER FL 33477 |
Ping Wang Rawson | officer: Chief Financial Officer | 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477 |
Michael P. Tarnok | director | KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
Arindam Bose | director | 4452 BELTWAY DRIVE, ADDISON TX 75001 |
Jack Kaye | director | C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022 |
Tom Juda | 10 percent owner | 410 S LUCERNE BLVD, LOS ANGELES CA 90020 |
John Steven Emerson | 10 percent owner | 1522 ENSLEY AVENUE, LOS ANGELES CA 90024 |
Nancy Juda | 10 percent owner | 410 S LUCERNE BLVD, LOS ANGELES CA 90020 |
From GuruFocus
By Marketwired • 07-26-2023
By sperokesalga sperokesalga • 05-10-2023
By sperokesalga sperokesalga • 03-01-2023
By sperokesalga sperokesalga • 04-26-2023
By Marketwired • 10-25-2023
By Marketwired • 07-24-2023
By Marketwired • 09-29-2023
By Value_Insider Value_Insider • 11-07-2022
By Stock market mentor Stock market mentor • 01-24-2023
By sperokesalga sperokesalga • 04-18-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.